private:srone
|
129916
|
Jun 1st, 2019 12:00AM
|
S.R. One Ltd
|
514
|
36.00
|
Open
|
Venture Capital & Private Equity
|
Jun 1st, 2019 02:20AM
|
Jun 1st, 2019 02:20AM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Mar 26th, 2018 12:00AM
|
S.R. One Ltd
|
433
|
35.00
|
Open
|
Venture Capital & Private Equity
|
Mar 26th, 2018 05:18PM
|
Mar 26th, 2018 05:18PM
|
|
Open
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Feb 17th, 2018 12:00AM
|
S.R. One Ltd
|
404
|
34.00
|
Open
|
Venture Capital & Private Equity
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Feb 16th, 2018 12:00AM
|
S.R. One Ltd
|
404
|
34.00
|
Open
|
Venture Capital & Private Equity
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Feb 15th, 2018 12:00AM
|
S.R. One Ltd
|
404
|
34.00
|
Open
|
Venture Capital & Private Equity
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Feb 14th, 2018 12:00AM
|
S.R. One Ltd
|
404
|
34.00
|
Open
|
Venture Capital & Private Equity
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Feb 13th, 2018 12:00AM
|
S.R. One Ltd
|
404
|
34.00
|
Open
|
Venture Capital & Private Equity
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Feb 12th, 2018 12:00AM
|
S.R. One Ltd
|
404
|
34.00
|
Open
|
Venture Capital & Private Equity
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Feb 11th, 2018 12:00AM
|
S.R. One Ltd
|
404
|
34.00
|
Open
|
Venture Capital & Private Equity
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|
private:srone
|
129916
|
Feb 10th, 2018 12:00AM
|
S.R. One Ltd
|
404
|
34.00
|
Open
|
Venture Capital & Private Equity
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 35 private and public companies and since our founding in 1985, we have invested over $830MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
|
|
|
|
|
|
|
|
|
|
SR One
|
|
Pharmaceuticals & Biotechnology
|